Skip to content
Varieties from the European CatalogueGrown in FranceSlow dryingDispatched within 24 working hours — before noonEU delivery — 24-72 hRight of withdrawal — 14 daysCertificate available — per batch
Canna·wikiMK-9470

ECS modulator (research)

Unscheduled

MK-9470

N-[(2S,3S)-3-(3-cyanophényl)-4-[4-(2-fluoroéthoxy)phényl]butan-2-yl]-2-méthyl-2-[(5-méthylpyridin-2-yl)oxy]propanamide

Aliases.[18F]MK-9470 · MK 9470

A positron emission tomography tracer of the human CB1 receptor, an inverse agonist at 0.7 nanomolar.

Updated on

Level of detail

Identifiers

Formula
C₂₉H₃₂FN₃O₃
Molar mass
489.60 g·mol⁻¹
CAS
947371-30-4
PubChem CID
11488705
Origin
A wholly synthetic compound. Its useful form is labelled with fluorine 18, a short-lived radionuclide produced in a cyclotron, which requires preparation within the hour preceding the examination and rules out any storage. It has no natural occurrence.
InChIKey
XIYPJXKEMLKFMD-HFZDXXHNSA-N

In plain terms

MK-9470 serves to photograph CB1 receptors in a living brain. Labelled with a short-lived radioactive atom, it binds to those receptors and makes their distribution visible to the camera. It is an imaging tool, not a therapy.

Receptors and activity

  • CB1
    IC50 humaine = 0,7 nM (Burns et coll. 2007)Inverse agonist
  • CB2
    Sélectivité CB1 ; usage comme radioligand sélectifModulator
  • Agonist
  • Partial agonist
  • Antagonist
  • Modulator
  • Inverse agonist

Hover over a row for the precise value (Ki, EC50…)

Subjective signature

Hover over an axis to read its definition.

  • Calm
    3
  • Clarity
    10
  • Sleep
    3
  • Appetite
    2
  • High
    3

Editorial estimate, not clinical.

Pharmacology

MK-9470 is the reference tracer for visualising the CB1 receptor in the human brain by positron emission tomography. Described in 2007 by Burns and colleagues, it is a selective inverse agonist of very high affinity, with a median inhibitory concentration of 0.7 nanomolar at the human receptor, labelled with fluorine 18. Its validation followed the complete approach expected of a radioligand. Autoradiography on macaque brain showed a distribution consistent with the established map of the receptor, dense in the cortex, the cerebellum, the basal ganglia, the substantia nigra and the hippocampus. Imaging in animals confirmed that distribution in vivo, with a ratio of total to non-specific binding of four to five in the putamen, a blockade of the signal by pretreatment with a potent inverse agonist and a displacement of already bound tracer, two criteria that establish specificity. In humans, the behaviour of the tracer proved very close to that observed in monkeys, with a reproducibility between two successive examinations of 7 per cent. The final demonstration concerned the expected use: oral administration of an inverse agonist under development produced a reduction of the signal proportional to the dose, that is a direct measure of receptor occupancy by the drug. The tracer subsequently served questions of human neurobiology, notably the demonstration of an increase in receptor availability with age, differing by sex, and the study of the receptor in chronic cannabis users.

Origin (research tool)

An entirely chemical route, described here by class only. The molecule is an amide built around a propylamine skeleton linking a cyanophenyl to a phenyl bearing a fluoroethoxy chain, the whole being linked by the amide function to a methylpyridyloxy motif. Isotopic labelling consists in introducing fluorine 18 onto the ethoxy chain, an operation carried out in one step in the automated versions of the preparation.

Structural classification

Class
ECS modulator (research)
Origin
A wholly synthetic compound. Its useful form is labelled with fluorine 18, a short-lived radionuclide produced in a cyclotron, which requires preparation within the hour preceding the examination and rules out any storage. It has no natural occurrence.
Status
Unscheduled

References

  1. 1.Burns et coll. 2007 : le [18F]MK-9470, traceur TEP du récepteur CB1 pour l'imagerie cérébrale humainePMID 17535893
  2. 2.Van Laere et coll. 2008 : augmentation de la liaison au CB1 avec l'âge chez l'humain, dépendante du sexePMID 18077184
  3. 3.Ceccarini et coll. 2015 : mesure par [18F]MK-9470 de la disponibilité du CB1 chez les consommateurs chroniques de cannabisPMID 24373053

Structured data

InChIKey
XIYPJXKEMLKFMD-HFZDXXHNSA-N
SMILES
CC1=CN=C(C=C1)OC(C)(C)C(=O)N[C@@H](C)[C@@H](CC2=CC=C(C=C2)OCCF)C3=CC=CC(=C3)C#N
Formula
C29H32FN3O3
Molar mass
489.60 g·mol⁻¹
CAS
947371-30-4
PubChem CID
11488705
Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.